Anti-SARS-CoV-2, Nucleocapsid (N) (COV19-5164)

Anti-SARS-CoV-2, Nucleocapsid (N) (COV19-5164)

Product No.: C457

- -
- -
Clone
COV19-5164
Target
SARS-CoV-2 Nucleocapsid (N)
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein, COVID-19
Isotype
Mouse IgG1
Applications
ELISA
,
IF

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactivity Species
SARS-CoV-2
Host Species
Mouse
Product Concentration
≥1.0 mg/ml
Purity
≥90%
Formulation
Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
This monoclonal antibody is purified by protein A chromatography or sequential differential precipitations.
Storage and Handling
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2-8°C Wet Ice
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA: 1:20-1:200
IF: 1:10-1:50
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Anti-SARS-CoV-2 (Clone COV19-5164) is specific for the nucleocapsid of SARS-CoV-2 including variants: UK B.1.1.7, SA B.1.351, Brazil P.1, B.1.617.2 (Delta), B.1.1.529 (Omicron) & BA.4. It is non-reactive with Influenza A, Influenza B, Adenovirus & MERS but does cross-react with SARS.
Antigen Distribution
The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.
Matched Pair
Best ELISA pair (capture/conjugate), COV19-5164/COV19-6429.
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and self-oligomerization, respectively 3, 4. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex 5. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways 6, 7. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein 8. It is also immunogenic, and antibodies 8,9 and memory T cells 10, 11 targeting the N protein are present in the sera of convalescent COVID-19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARS-CoV-2 12. The N protein also contributes to immune evasion by antagonizing antiviral RNAi 13, suggesting its potential value as a targeted therapeutic.

Antigen Details

NCBI Gene Bank ID
Research Area
Infectious Disease
.
Matched Pair
.
Seasonal and Respiratory Infections
.
Viral

References & Citations

1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.
3. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
4. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.
5. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.
6. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.
7. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.
8. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
9. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
11. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.
12. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.
13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.
14. Gorshkov, Kirill, et al. "SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening." ACS pharmacology & translational science 5.1 (2022): 8-19. Link
15. Park, Jun-Gyu, et al. "Animal Models of COVID-19: Transgenic Mouse Model." SARS-CoV-2. Humana, New York, NY, 2022. 259-289. Link
Indirect Elisa Protocol
IF

Formats Available

- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.